ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced positive results from a Phase III bioequivalence study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE